broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K33622447-066-01-9 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.350971 | 1.614489 | 0.493428 | 0.755264 | 0.257897 | 0.545824 | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-001128 |
BRD-K36627727-001-05-4 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 1.002902 | -0.583249 | -0.010864 | 1 | 0.01417 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-001128 |
BRD-K37379014-001-02-0 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.371134 | 0.949363 | 0.213409 | 0.700722 | 0.001547 | 0.006453 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-001128 |
BRD-K38852836-001-02-1 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.083661 | 1.665957 | 0.744254 | 0.418253 | 0.005277 | 0.00589 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-001128 |
BRD-K39974922-001-04-3 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.610682 | 0.806536 | 0.029297 | 0.791958 | 0.055182 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-001128 |
BRD-K41859756-001-06-8 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.083596 | 0.979033 | 0.713325 | 0.317317 | 0.001654 | 0.001993 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-001128 |
BRD-K42805893-001-04-9 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 2.548249 | -0.213138 | -0.0905 | 1 | 0.000039 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-001128 |
BRD-K42898655-001-01-8 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.102988 | 0.165255 | 0.119458 | 0.485897 | 0.000747 | 0.003016 | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-001128 |
BRD-K44227013-001-06-4 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.187221 | 6.151799 | 0.533593 | 0.748605 | 0.49704 | 0.536432 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-001128 |
BRD-K44827188-001-06-0 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 1.400947 | 0.112111 | 0.019364 | 1 | 0.122801 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-001128 |
BRD-K50010139-001-01-5 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 1.345968 | -0.010835 | -0.068567 | 1 | 0.158698 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-001128 |
BRD-K51313569-001-07-8 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.290089 | 0.466752 | 0.296212 | 0.512932 | 0.007834 | 0.050298 | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-001128 |
BRD-K51791723-003-01-7 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.112942 | 1.675185 | 0.644913 | 0.626821 | 0.168724 | 0.196586 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-001128 |
BRD-K51967704-001-03-6 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.056852 | 2.28869 | 0.717808 | 0.593046 | 0.151861 | 0.160085 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-001128 |
BRD-K52313696-001-12-3 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.460513 | 0.198179 | -0.05771 | 0.684977 | 0.01242 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-001128 |
BRD-K53972329-001-07-0 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.73034 | 1.763662 | 0.061292 | 0.911398 | 0.413117 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-001128 |
BRD-K54256913-001-08-7 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.286856 | 1.498247 | 0.284924 | 0.765551 | 0.413843 | 0.731119 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-001128 |
BRD-K55187425-236-05-2 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.092169 | 0.766067 | 0.532062 | 0.46041 | 0.029737 | 0.038798 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-001128 |
BRD-K58550667-001-08-7 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.13047 | 2.88017 | 0.725999 | 0.66259 | 0.014465 | 0.016066 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-001128 |
BRD-K59317601-001-05-5 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.150589 | 0.540348 | 0.077589 | 0.350919 | 0.0033 | 0.006404 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-001128 |
BRD-K59369769-001-22-9 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.357357 | 3.222909 | -0.290866 | 0.617425 | 0.03097 | 0.045704 | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-001128 |
BRD-K60866521-001-07-1 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.927423 | 2.479877 | 0.074452 | 0.945266 | 0.006623 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-001128 |
BRD-K60997853-001-02-3 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | -0.121114 | 0.317523 | 0.41414 | 0.481559 | 0.137311 | 0.069347 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-001128 |
BRD-K61192372-001-08-9 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 1.058067 | -0.680165 | -0.252259 | 1 | 0.458671 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-001128 |
BRD-K62008436-001-23-9 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.464238 | 0.851482 | 0.158712 | 0.573775 | 0.000218 | 0.004838 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-001128 |
BRD-K62196610-001-01-6 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.311016 | 4.350253 | 0.58802 | 0.79934 | 0.59227 | 0.740709 | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-001128 |
BRD-K62627508-001-01-5 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.200727 | 4.539811 | 0.740429 | 0.637162 | 0.122097 | 0.136711 | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-001128 |
BRD-K63712959-001-01-8 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 18.300192 | 0.292145 | -0.010263 | 1 | 22,669,130,153,368,400,000 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-001128 |
BRD-K66175015-001-12-4 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 1.011494 | 0.550344 | -0.097696 | 1 | 0.003717 | null | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-001128 |
BRD-K67844266-003-01-9 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.035169 | 1.032225 | 0.384194 | 0.761396 | 0.987148 | 1.059421 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-001128 |
BRD-K69776681-001-03-8 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.144362 | 8.285027 | 0.746098 | 0.592116 | 0.097918 | 0.102028 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-001128 |
BRD-K70301465-001-05-9 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.477841 | 3.848065 | 0.112343 | 0.811663 | 0.301867 | 0.678478 | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-001128 |
BRD-K73838513-003-05-5 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.66679 | -0.326875 | -0.348361 | 0.849326 | 0.038606 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-001128 |
BRD-K74514084-003-09-2 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.35267 | 2.246352 | 0.470679 | 0.761582 | 0.280386 | 0.483054 | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-001128 |
BRD-K75009076-001-02-1 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.453162 | 0.239655 | 0.045368 | 0.706066 | 0.038927 | null | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-001128 |
BRD-K76674262-001-03-3 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.170639 | 2.270493 | 0.87685 | 0.538763 | 0.045296 | 0.054439 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-001128 |
BRD-K78431006-001-15-1 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.173978 | 0.711026 | 0.593339 | 0.605319 | 0.098253 | 0.179288 | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-001128 |
BRD-K81016934-001-02-0 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.363286 | 4.839621 | 0.42472 | 0.426435 | 0.001594 | 0.002084 | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-001128 |
BRD-K81473043-001-19-5 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.084114 | 1.459422 | 0.679402 | 0.51814 | 0.003786 | 0.004295 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-001128 |
BRD-K82818427-001-04-8 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 1.315565 | 0.451756 | -0.046164 | 1 | 0.088238 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-001128 |
BRD-K83029223-001-01-3 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.427066 | 3.120012 | 0.500368 | 0.637664 | 0.00135 | 0.002502 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-001128 |
BRD-K83988098-001-02-0 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.01623 | 0.853408 | 0.631484 | 0.564224 | 0.002159 | 0.002245 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-001128 |
BRD-K85606544-001-09-1 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 1.157478 | -0.022844 | -0.088353 | 1 | 44,743,381,099.33544 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-001128 |
BRD-K86972824-001-01-4 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.976992 | -0.113819 | -0.007403 | 0.985465 | 10.057352 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-001128 |
BRD-K88510285-001-17-8 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.147408 | 1.026074 | 0.544474 | 0.510008 | 0.00937 | 0.01317 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-001128 |
BRD-K89014967-001-04-3 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.094847 | 1.474369 | 0.511067 | 0.43861 | 0.024252 | 0.027971 | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-001128 |
BRD-K92441787-001-04-1 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.658484 | -6.39745 | 0.412593 | 0.926857 | 0.004875 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-001128 |
BRD-K95142244-001-01-5 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.710936 | -10.164425 | 0.439863 | 0.773789 | 1.212207 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-001128 |
BRD-K99616396-001-05-1 | ACH-001128 | MON_SOFT_TISSUE | MTS010 | 1 | 0.762166 | 9.577612 | 0.126225 | 0.845707 | 0.01844 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-001128 |
BRD-A25234499-001-19-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.210759 | -4.161841 | 0.181864 | 1 | 0.077353 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-001145 |
BRD-A70858459-001-01-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.96522 | -0.023817 | -0.003369 | 0.978715 | 16,242,641.350229 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-001145 |
BRD-A74914197-001-02-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.234559 | 5.448135 | 0.87434 | 0.634254 | 0.006052 | 0.006798 | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-001145 |
BRD-K02113016-001-19-6 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.269444 | 6.367994 | 0.555639 | 0.917916 | 3.361337 | 3.795824 | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-001145 |
BRD-K02130563-001-11-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.123659 | 7.816189 | 0.565859 | 0.581165 | 0.096751 | 0.100331 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-001145 |
BRD-K03390685-001-01-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.837694 | -0.142221 | -0.029513 | 0.893726 | 8.350409 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-001145 |
BRD-K03406345-001-21-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.895923 | -0.081185 | -0.001476 | 0.929534 | 797.247299 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001145 |
BRD-K03449891-001-08-6 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.493273 | 4.92071 | 0.410574 | 0.94843 | 1.075636 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-001145 |
BRD-K03765900-001-01-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.140486 | 4.473723 | 0.61929 | 0.852009 | 1.880928 | 2.024851 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-001145 |
BRD-K05804044-001-18-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.014184 | -0.036058 | -0.0051 | 1 | 19.986227 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-001145 |
BRD-K06814349-304-02-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.264157 | 10.702626 | 0.592598 | 0.84666 | 1.323477 | 1.419741 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-001145 |
BRD-K08109215-001-06-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.531673 | 2.27356 | 0.473584 | 0.804355 | 0.173511 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-001145 |
BRD-K08542803-001-02-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.195211 | 5.029159 | 0.633293 | 0.751941 | 0.50225 | 0.554198 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-001145 |
BRD-K08547377-001-04-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.089361 | 1.895171 | 0.885749 | 0.542638 | 0.076421 | 0.084787 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-001145 |
BRD-K08703257-001-13-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.738309 | 1.488259 | -0.009401 | 0.987864 | 10.322396 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-001145 |
BRD-K08799216-001-05-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.735992 | -6.780126 | -0.128468 | 0.868807 | 0.075808 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-001145 |
BRD-K09951645-001-11-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.720599 | 0.178765 | -0.084622 | 0.844387 | 0.020071 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-001145 |
BRD-K11267252-001-05-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.30696 | 0.244262 | -0.065888 | 1 | 0.881806 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-001145 |
BRD-K11630072-001-13-2 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.85575 | 0.424792 | 0.056316 | 0.928421 | 0.081894 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-001145 |
BRD-K12184916-001-19-6 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.344003 | 1.785095 | 0.397394 | 0.501649 | 0.006064 | 0.011645 | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-001145 |
BRD-K13049116-001-04-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.622819 | 2.792594 | 0.44668 | 0.93798 | 2.036125 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-001145 |
BRD-K13390322-001-06-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.093678 | 3.966427 | 0.678203 | 0.75363 | 0.715001 | 0.753397 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-001145 |
BRD-K13514097-001-04-6 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.494219 | -0.29825 | -0.087863 | 0.873883 | 0.001105 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-001145 |
BRD-K13662825-001-07-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.094743 | 4.265991 | 0.823174 | 0.558851 | 0.022118 | 0.023235 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-001145 |
BRD-K14109347-001-03-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.145675 | 4.568324 | 0.566057 | 0.894758 | 3.028379 | 3.265498 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-001145 |
BRD-K15179879-001-03-2 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.153623 | 9.605225 | 0.893778 | 0.488134 | 0.028254 | 0.029355 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-001145 |
BRD-K15600710-066-05-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.295923 | 10.076685 | 0.459091 | 0.75354 | 0.328635 | 0.359199 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-001145 |
BRD-K16730910-001-10-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.735744 | -2.061956 | 0.16775 | 0.94372 | 0.004786 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-001145 |
BRD-K17555800-003-02-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.018092 | -0.327666 | -0.003599 | 1 | 0.595188 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-001145 |
BRD-K17610631-001-03-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.71005 | 3.938688 | 0.600113 | 1 | 0.152686 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-001145 |
BRD-K17743125-001-08-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.08291 | 3.565377 | 0.479581 | 0.858974 | 2.251561 | 2.369019 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-001145 |
BRD-K17894950-001-14-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.151708 | 0.049355 | -0.007168 | 1 | 0.001824 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-001145 |
BRD-K18961567-001-01-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.097649 | 2.61402 | 0.638854 | 0.865855 | 2.384026 | 2.590661 | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-001145 |
BRD-K19540840-001-09-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.250368 | 0.762616 | 0.411931 | 0.720939 | 0.290378 | 0.721993 | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-001145 |
BRD-K19687926-001-04-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.695756 | -0.001456 | -0.014716 | 0.816024 | 511,481,776,227,362,750,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-001145 |
BRD-K19796430-001-05-6 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.085007 | 0.065951 | -0.003592 | 1 | 0.00222 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-001145 |
BRD-K22064724-001-01-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.049154 | 0.617045 | 0.707349 | 0.614791 | 0.21748 | 0.257188 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-001145 |
BRD-K22822991-001-02-3 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.799408 | 5.363327 | 0.129367 | 0.866861 | 0.015944 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-001145 |
BRD-K23228615-001-02-8 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.241855 | 0.790059 | 0.76443 | 0.749822 | 0.448334 | 1.035143 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-001145 |
BRD-K23984367-001-07-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.165615 | 0.245665 | 0.062818 | 1 | 0.013856 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-001145 |
BRD-K26026438-001-01-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.750858 | 1.452818 | 0.127471 | 0.882742 | 0.103894 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-001145 |
BRD-K26657438-001-15-2 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.76761 | 3.557368 | 0.021966 | 0.925145 | 0.438949 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-001145 |
BRD-K28822270-001-03-7 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.227728 | 4.563737 | 0.373573 | 0.881043 | 2.347565 | 2.681993 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-001145 |
BRD-K30577245-001-05-0 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.186409 | 4.276584 | 0.806964 | 0.503667 | 0.001677 | 0.00187 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-001145 |
BRD-K31698212-001-02-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.065385 | -0.021926 | -0.017763 | 1 | 22,561.184342 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-001145 |
BRD-K31928526-001-02-1 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.356049 | 2.504122 | 0.566389 | 0.770516 | 0.314813 | 0.517606 | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-001145 |
BRD-K33379087-001-07-5 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.146007 | 6.942785 | 0.698666 | 0.843099 | 1.681326 | 1.767082 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-001145 |
BRD-K33610132-001-02-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.291139 | -0.337312 | 0.075388 | 1 | 0.012831 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-001145 |
BRD-K33622447-066-01-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.216928 | 2.826669 | 0.550805 | 0.79265 | 0.765781 | 0.936506 | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-001145 |
BRD-K35520305-001-16-9 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 1.140552 | -0.04945 | -0.098962 | 1 | 0.000073 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-001145 |
BRD-K36627727-001-05-4 | ACH-001145 | OC316_OVARY | MTS010 | 1 | 0.992342 | 0.237959 | -0.080072 | 0.994394 | 0.000749 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-001145 |
Subsets and Splits